Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session.

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare sector as a whole. This time last year, the biotech ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its long-awaited non-opioid painkiller. The approval of the company’s oral non ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Monday,RTT News reports.

ClearBridge Growth Strategy highlighted stocks like Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), in the third quarter 2024 investor letter. Vertex Pharmaceuticals Incorporated (NASDAQ ...

Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 10 unusual trades. Delving into the details, we found 20% of traders were bullish, while 80% showed bearish tendencies.